Resolute DES (Medtronic) delivers clinical benefits out to two years - 25-Mar-2012

The Resolute drug-eluting stent (DES), from Medtronic, maintains a powerful and persistent treatment effect for a wide variety of patients with Coronary Artery Disease, including those with Diabetes. A new study that includes 2 years of follow-up, the RESOLUTE US clinical study and two pooled analyses of the entire Resolute clinical program –– one on safety measures for all patients (RESOLUTE Pooled Safety), the other for all patients with diabetes (RESOLUTE Pooled Diabetes) -- reveals low rates of target lesion failure (TLF), target lesion revascularization (TLR) and definite/probable stent thrombosis (def/prob ST). In total, the program enrolled 5,130 patients who received a Resolute DES; about one third of which had Diabetes. Results show very low rates of clinically-driven TLR (4.7%) and def/prob ST (0.9%), despite 46 percent of the patients in the RESOLUTE program being considered complex, as well as consistently low event rates out to two years despite the higher-risk nature of the Diabetes patient population. Results were presented at the 61st Annual Scientific Session & Expo of the American College of Cardiology.